Troutman Pepper attorneys explain the potential benefits in FDAs new Emerging Drug Safety Technology Program.
FDA plans to ask its Vaccines and Related Biological Products Advisory Committee to discuss potential safety concerns related to pediatric respiratory...
The National Institutes of Health ends a trial of an mpox antiviral drug that failed to produce an efficacy signal.
Federal Register notice: FDA announces the revocation of B. Braun Medical emergency use authorizations for three Covid-related devices.
A Paragon Health Institute white paper suggests an approach to regulating healthcare artificial intelligence that it says builds on existing FDA regul...
Based on FDA feedback, NeuroSense Therapeutics says it will begin a Phase 3 study of PrimeC (ciprofloxacin and celecoxib) for treating amyotrophic lat...
Johnson & Johnson reports data from its Phase 3 CARTITUDE-4 study that show Carvykti significantly increased minimal residual disease (MRD) negativity...
